We are investigating Vaxart, Inc. (VXRT) (“Vaxart” or the “Company”) for potential violations of the federal securities laws. On July 25, 2020, the New York Times published an article entitled “Corporate Insiders Pocket $1 Billion in Rush for Coronavirus Vaccine.” The New York Times article reported that Vaxart’s “[c]ompany insiders, who weeks earlier had received stock options worth a few million dollars, saw the value of those awards increase sixfold” when the Company announced that its COVID-19 vaccine had been selected by the U.S. government to be part of Operation Warp Speed, the flagship federal initiative to quickly develop drugs to combat COVID-19. On this news, Vaxart’s stock price fell $1.13 per share, or 9.19%, to close at $11.16 per share on July 27, 2020.